Bài viết Đặc điểm đột biến gen EGFR trong mẫu huyết tương ở bệnh nhân ung thư phổi không tế bào nhỏ sau điều trị TKI thế hệ I, II tại Bệnh viện Bạch Mai mô tả tình trạng đột biến EGFR mẫu huyết tương và phân tích một số yếu tố liên quan ở những bệnh nhân tiến triển sau điều trị TKIs. | VNU Journal of Science Medical and Pharmaceutical Sciences Vol. 38 No. 1 2022 74-81 Original Article Characteristics of EGFR Mutations in Plasma Samples in Non-Small Cell Lung Cancer Patients after Treatment with 1st and 2nd Generation of TKI at Bach Mai Hospital Nguyen Thuan Loi1 Pham Cam Phuong1 Do Dinh Hung2 1 The Nuclear Medicine and Oncology Center Bach Mai Hospital 78 Giai Phong Dong Da Hanoi Vietnam 2 VNU University of Medicine and Pharmacy 144 Xuan Thuy Cau Giay Hanoi Vietnam Received 02 September 2021 Revised 13 September 2021 Accepted 13 September 2021 Abstract This study aims to describe EGFR mutation status detected in plasma samples and analyze some related factors in non-small cell lung cancer patients after treatment with the generation I and II Tyrosine Kinase inhibitors at Bach Mai Hospital. Patients and methods A retrospective descriptive study on 75 patients with non-small cell lung cancer tested for EGFR mutations in plasma after treatment with 1st or 2nd EGFR-TKIs in 2019-2020. Results EGFR mutations were detected in plasma samples the T790M mutation accounted for and is accompanied by a sensitive mutation TKI The T790M mutations ratio after treatment was higher than before treatment with TKIs p lt the median total duration of EGFR-TKI treatment was significantly longer in patients with T790M mutation than in those without months vs months p the T790M mutation ratio was higher in patients with a deletion on exon 19 than in L858R mutation on exon 21 p in Erlotinib treatment group higher than in Gefitinib and Afatinib treatment group vs. with and p . Conclusions EGFR mutation plasma test helps to monitor disease progression and detect resistance mutations T790M in NSCLC patients after TKI generation I and II. Keywords non-small cell lung cancer EGFR mutations T790M mutations TKIs. _ Corresponding author. E-mail address camphuongmd@ https 2588-1132 74
